Lulizumab pegol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lulizumab pegol
DrugBank Accession Number
DB15441
Background

Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).

Type
Biotech
Groups
Investigational
Synonyms
  • BMS-931699
  • Lulizumab pegol

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Lulizumab pegol.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Lulizumab pegol.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Lulizumab pegol.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lulizumab pegol.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Lulizumab pegol.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
LCT264LTYE
CAS number
1421830-13-8

References

General References
Not Available
Wikipedia
Lulizumab_pegol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedOtherLupus1
2TerminatedTreatmentSjögren's Syndrome (SS)1
2WithdrawnTreatmentKidney Transplantation / Renal Transplant Recipient Patients1
1TerminatedOtherHealthy Volunteers (HV)1
1, 2CompletedTreatmentLiving-Donor Kidney Transplants / Renal Transplant Recipient Patients1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 15:32 / Updated at February 21, 2021 18:55